Vermillion's Q4 Loss Widens, Revenues Fall in Anticipation of Dx Launch

Mar 05, 2008

NEW YORK (GenomeWeb News) – Vermillion yesterday reported minimal revenues for the fourth quarter of 2007, accompanied by a wider net loss, as it continues to take steps to launch its first diagnostic tests later this year.

Vermillion reiterated in its financial report that it “anticipates no major revenue until its diagnostic tests are commercialized” due to the sale of its proteomics tools business to Bio-Rad in November 2006.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Main menu